Treatment and outcome of patients with extragonadal germ cell tumours - the Norwegian Radium Hospital's experience 1979-94
1998

Treatment and outcome of patients with extragonadal germ cell tumours

Sample size: 48 publication Evidence: moderate

Author Information

Author(s): S Dueland, AE Stenwig, A Heilo, J Hoie, S OUS, SD Foss

Primary Institution: The Norwegian Radium Hospital

Hypothesis

Some cases of retroperitoneal EGGCT may be due to a primary testicular cancer with metastases.

Conclusion

EGGCT is a potentially curable disease, even in patients with very advanced disease.

Supporting Evidence

  • 27 out of 42 patients receiving four or more chemotherapy cycles were rendered tumour free.
  • The 5-year overall survival for all 48 patients was 60%.
  • Late relapses were observed in three patients.

Takeaway

This study looked at patients with a rare type of cancer that starts outside the testicles. Many of them can be treated successfully, but older patients need special care.

Methodology

The study reviewed 48 patients treated for EGGCT, analyzing their treatment responses and outcomes over a 15-year period.

Limitations

The study is limited by its retrospective nature and the small sample size.

Participant Demographics

Median age of patients was 36 years, with a range from 19 to 75 years; 2 patients were women.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 46-74%

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication